Drugs / DREP-HIV-PT1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04844775 | Aug 2022 → Sep 2024 | — | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DREP-HIV-PT1 | “The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1.” NCT04844775 ↗ |
| Modality | Vaccine | “The DREP-HIV-PT1 is a vaccine designed to elicit an immune response” NCT04844775 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT04844775 ↗ |